NR0B2 Gene Test Service
InquiryOverview
In the field of obesity and metabolic disease research, Protheragen provides a range of advanced Obesity Causation Analysis services designed to provide insight into the role of relevant genes in the development of disease. The NR0B2 (SHP) gene plays an important role in regulating energy balance and metabolic processes. Our services are designed to provide comprehensive NR0B2 gene testing for our clients, contributing to the in-depth development of obesity and metabolic disease research.
Unlocking the Secrets of the NR0B2 Gene to Push the Frontiers of Obesity Research
Our research team focuses on unraveling the mechanisms of the NR0B2 gene in a variety of physiological and pathological processes, including metabolic regulation, hormone secretion, cellular dysfunction, and obesity. We provide professional gene testing through gene sequencing, variant analysis, functional validation, and multi-omics studies.
Sample Collection and Gene Sequencing
- Sample pre-processing: Our company has a professional research team to provide sample extraction and isolation services.
- Gene sequencing: We provide high-throughput sequencing services to obtain detailed gene sequence information.
- Mutation site analysis: Based on the sequencing results, our data analysts use advanced bioinformatics tools to perform precise mutation analysis of the target loci. This includes determining the type of mutation (e.g., point mutation, insertion, or deletion), mutation frequency, and location distribution.
Gene Expression Detection
- Lipid and protein profiling: We provide blood index testing, tissue freezing, sectioning, and staining services. Our researchers offer sample isolation services by the Folch extraction method. For extracted samples, we offer homogenization, centrifugation, and mass spectroscopy (MS) analysis services.
Metabolic Pathway Analysis
- The NR0B2 gene is closely related to hepatic glucose metabolism and lipid metabolism. We provide metabolite distribution and characterization services to comprehensively study obesity.
Workflow
Applications
- Based on the fact that the NR0B2 gene plays an important regulatory role in hepatic glucose-lipid metabolism, the intrahepatic NR0B2 gene can be used as a new therapeutic target for metabolic diseases such as diabetes mellitus and nonalcoholic fatty liver disease.
- The NR0B2 gene test can be used to explore the specific roles of different factors in neurodevelopment, functional maintenance, and pathological processes such as obesity.
- The NR0B2 gene test can be used to characterize multiple metabolic pathways, including bile acids, cholesterol, triglycerides, and glucose.
Advantages of Us
- We have established a strict quality control system in all aspects of sample processing, DNA extraction, sequencing, and data analysis to ensure the accuracy of the test results.
- We have a dedicated bioinformatics team to help our clients with data visualization.
- We offer personalized gene testing routes based on our clients' research needs and uses.
Comprehensive Anti-Obesity Solutions to Boost Your Research
Targets and Anti-Obesity Therapy
Preclinical Studies of Anti-Obesity Therapeutics
Publication Data
Technology: RNA sequencing, MS, Luciferase reporter assay, Real-time polymerase chain reaction (RT-qPCR)
Journal: Nature Communications
Published: 2020
IF: 14.7
Results: This literature focuses on the epigenetic regulation of adipogenic gene expression by small heterodimer partner (SHP/NR0B2) and DNA methyltransferase-3a (DNMT3A) in non-alcoholic fatty liver disease (NAFLD). It was found that in the liver, SHP proteins interact with DNMT3A proteins to co-regulate the expression of adipogenic genes. When SHP protein levels were elevated, the methylation level of adipogenic genes by DNMT3A also increased, which in turn repressed gene expression. In conclusion, the SHP/NR0B2 gene plays a key role in the transcriptional repression of adipogenesis.
Fig.1 Mapping of inhibitory effects and induced expression analysis. (Kim, et al., 2020)
Frequently Asked Questions
-
In which tissues is the NR0B2 gene primarily expressed?
The NR0B2 gene is major expressed in the adrenal glands, heart, liver, duodenum, small intestine, kidneys, and spleen.
-
What diseases is the NR0B2 gene associated with?
The NR0B2 gene is associated with obesity, hemopneumothorax, cholestasis, Swyer syndrome, intrahepatic cholestasis of pregnancy, progressive familial intrahepatic cholestasis, cholangitis, primary sclerosing, and type 2 diabetes mellitus.
Based on advanced sequencing tools, Protheragen provides high-quality genetic testing services to meet our clients' needs in hereditary obesity research. Whether you want to analyze gene sequences or have questions about mutation sites, please feel free to contact us.
Reference
- Kim, Y.C.; et al. Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. Nature Communications. 2020, 11(1): 5969. (CC BY 4.0)
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.